{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1314",
  "slug": "immunotherapy-tumor-neighborhood",
  "edition": "2026-11-10T00",
  "url": "https://hangingcontext.com/stories/2026-11-10/immunotherapy-tumor-neighborhood/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Immunotherapy's next lever is the tumor's neighborhood, not just the checkpoint.",
  "headline": "Four preprints point immunotherapy at the tumor's neighborhood",
  "dek": "A failed melanoma biomarker, a switch receptor that spares healthy tissue, a laser-built bladder vaccine and organoids that hide cancer signals all point the same way: context around the tumor decides what treatment does.",
  "published_at": "2026-11-10T00:45:13Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 4 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 4,
  "publishers": [
    "biorxiv-cancer-immunology-translation",
    "biorxiv-cell-molecular-mechanisms"
  ],
  "sources": [
    "biorxiv-cancer-immunology-translation",
    "biorxiv-cell-molecular-mechanisms"
  ],
  "distinct_source_count": 2,
  "key_facts": [
    {
      "text": "In a preprint, a proposed high-glycolysis, low-interferon state did not consistently predict disease control in melanoma patients treated with PD-1 blockade across three cohorts.",
      "cites": [
        {
          "claim_ids": [
            "1794245120207277678"
          ],
          "manifest_id": "1794244806301274362"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, PD-1 chimeric switch receptor T-cells showed reduced killing of healthy human cells, including hepatocytes and cardiomyocytes, compared with antibody-based PD-L1 CAR T-cells.",
      "cites": [
        {
          "claim_ids": [
            "1794233679871215295"
          ],
          "manifest_id": "1794233409200214618"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, vaccination with laser-killed MB49 bladder cancer cells reduced tumor incidence and growth in mouse bladder cancer models.",
      "cites": [
        {
          "claim_ids": [
            "1794245127404278415"
          ],
          "manifest_id": "1794244806302274363"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, high EGF at 50 ng/mL masked the effects of acute oncogenic activity in intestinal organoids, while lower EGF levels and EREG revealed them.",
      "cites": [
        {
          "claim_ids": [
            "1794264251488460977",
            "1794264251493460979"
          ],
          "manifest_id": "1794263955028460196"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "The pattern across four preprints",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794244806301274362"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794233409200214618"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794244806302274363"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794263955028460196"
            }
          ],
          "markdown": "Four bioRxiv preprints published on 9 November look at immunotherapy from four different directions, and they share one conclusion: what surrounds a tumor decides what a treatment does. One tests whether a proposed melanoma biomarker holds up. One rebuilds a T-cell receptor so it can tell tumor from healthy tissue. One builds a cancer vaccine with lasers instead of drugs. And one shows that the growth factors bathing an organoid can hide or reveal a cancer mutation. All four are preprints, so none of this is peer-reviewed yet. Read together, they argue that the next gains in immunotherapy will come from managing context, not only from finding new targets."
        }
      ]
    },
    {
      "heading": "A biomarker that did not hold up",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794245120207277678",
                "1794245120214277679",
                "1794245120224277680"
              ],
              "manifest_id": "1794244806301274362"
            }
          ],
          "markdown": "The melanoma preprint is the cautionary tale. Wu and Yang tested a proposed state, high glycolysis combined with low interferon signaling, as a predictor of poor disease control in melanoma patients treated with PD-1 blockade. Across three independent cohorts, GSE91061, GSE78220 and the Liu cohort, the association did not hold up consistently. The preprint reports that bulk interferon scores are negatively correlated with DNA-derived tumor purity, with a Spearman rho of -0.671, which suggests the score partly reflects how much tumor is in the sample rather than how the tumor behaves. Cellular correlations in single-cell analyses were also sensitive to the choice of gene background and rank scoring methods. The implication is plain: a biomarker built on bulk transcriptomic scores needs purity adjustment and testing across scoring methods before anyone leans on it."
        }
      ]
    },
    {
      "heading": "A receptor that reads the room",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794233679871215295",
                "1794233679873215296",
                "1794233679877215297"
              ],
              "manifest_id": "1794233409200214618"
            }
          ],
          "markdown": "The PD-1 chimeric switch receptor preprint takes the opposite approach: instead of questioning a measurement, it rebuilds the therapy. The platform engineers T-cells with receptors designed to discriminate between PD-L1 on tumors and PD-L1 on healthy tissue, aiming to widen the gap between effect and harm. In the preprint's tests, the engineered cells showed reduced killing of primary human small airway epithelial cells, astrocytes, renal epithelial cells, hepatocytes and cardiomyocytes compared with antibody-based PD-L1 CAR T-cells. The same cells targeted both tumor cells and immunosuppressive myeloid cells in 3D multicellular tumor organoids, and they suppressed tumor growth and prolonged survival in orthotopic breast cancer and patient-derived glioblastoma models. What remains untested is the long term: persistence of the construct and whether the construct itself provokes an immune response."
        }
      ]
    },
    {
      "heading": "Building the vaccine, and seeing the tumor",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794245127400278413",
                "1794245127403278414",
                "1794245127404278415"
              ],
              "manifest_id": "1794244806302274363"
            }
          ],
          "markdown": "The bladder cancer preprint changes the manufacturing step rather than the biology. Researchers used laser-induced vapor nanobubbles generated from dextran-coated iron oxide nanoparticles to kill tumor cells without drugs, a photomechanical method. The killing triggered immunogenic cell death, with calreticulin exposure and release of ATP and HMGB1 in bladder cancer cells. Vaccination with the killed MB49 cells reduced tumor incidence and growth in mouse bladder cancer models and increased infiltration of CD8 T cells and inflammatory monocytes, while splenocyte tests showed stronger antitumor activity. Toxicity follow-up in the preprint ran 7 days, and human testing has not happened."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794264251488460977",
                "1794264251492460978",
                "1794264251493460979"
              ],
              "manifest_id": "1794263955028460196"
            }
          ],
          "markdown": "The organoid preprint shows why the neighborhood matters even before treatment starts. Researchers engineered mouse small intestinal organoids with inducible KRASG12V and beta-Ctn4A, then varied the growth factors around them. At high EGF, 50 ng/mL, acute oncogenic activity did not alter organoid growth. At sub-saturating EGF, 0.5 to 5 ng/mL, and with EREG, the same oncogenes produced different crypt and villus development. Crypt domain spatial distribution was independent of crypt area and required EGF or EREG signaling. The practical point, drawn from the preprint's own takeaways, is that organoid screens for early transformation need calibrated growth-factor levels, or the assay can hide the very change it is meant to detect."
        }
      ]
    },
    {
      "heading": "What to watch",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794245120207277678"
              ],
              "manifest_id": "1794244806301274362"
            },
            {
              "claim_ids": [
                "1794233679877215297"
              ],
              "manifest_id": "1794233409200214618"
            },
            {
              "claim_ids": [
                "1794245127404278415"
              ],
              "manifest_id": "1794244806302274363"
            },
            {
              "claim_ids": [
                "1794264251493460979"
              ],
              "manifest_id": "1794263955028460196"
            }
          ],
          "markdown": "Taken together, the four preprints sketch a research agenda rather than a treatment. The melanoma work says to distrust a transcriptomic signature until purity and scoring are accounted for. The switch receptor work says the safety problem in PD-L1 cell therapy may be eased by engineering discrimination into the receptor, but only animal and organoid data exist so far. The vaccine work says manufacturing can be physical rather than chemical, if the mouse results travel. And the organoid work says the assay conditions are part of the result. For professionals watching this space, the near-term signal is not a product launch. It is whether these groups, or others, repeat the work in patient-derived material and in the clinic."
        }
      ]
    }
  ],
  "unresolved": [
    "No clinical validation for the PD-1 switch receptor platform, the vapor nanobubble vaccine, or the organoid findings.",
    "Long-term persistence and potential immunogenicity of the chimeric switch receptor construct remain to be evaluated.",
    "No patient-derived organoid data for the EGF and EREG findings.",
    "Whether the melanoma glycolysis and interferon state has any predictive value in a specific subgroup was not established."
  ],
  "decision_card": {
    "not_for": [
      "Anyone looking for a treatment ready for patients, or for peer-reviewed results."
    ],
    "useful_for": [
      "Researchers working on immunotherapy biomarkers, cell therapy safety, cancer vaccines, or organoid models."
    ],
    "compare_against": [
      "Peer-reviewed PD-1 blockade biomarker studies that adjust for tumor purity.",
      "Clinical whole-cell vaccine trials."
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-10T00"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794244806301274362",
    "1794233409200214618",
    "1794244806302274363",
    "1794263955028460196"
  ],
  "manifests": [
    {
      "title": "Glycolysis and interferon transcription in melanoma immunotherapy",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.30.763008v1.full",
      "manifest_id": "1794244806301274362",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-09"
    },
    {
      "title": "A Standalone PD-1 Chimeric Switch Receptor T-Cell Platform Expands the Therapeutic Window of PD-L1 Targeting in Solid Tumors",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.05.764663v1.full",
      "manifest_id": "1794233409200214618",
      "source_name": "biorxiv-cell-molecular-mechanisms",
      "published_date": "2026-11-09"
    },
    {
      "title": "Photomechanical engineering of immunogenic whole-cell vaccines by laser-induced vapor nanobubbles for bladder cancer prophylaxis",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.06.764866v1.full",
      "manifest_id": "1794244806302274363",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-09"
    },
    {
      "title": "EGF and EREG regulate early oncoprotein-mediated tissue transformation in intestinal organoids.",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.07.764837v1.full",
      "manifest_id": "1794263955028460196",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-09"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794244806301274362",
      "1794233409200214618",
      "1794244806302274363",
      "1794263955028460196"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794244806301274362",
      "all": "for id in 1794244806301274362 1794233409200214618 1794244806302274363 1794263955028460196; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-10/immunotherapy-tumor-neighborhood/",
    "json": "https://hangingcontext.com/stories/2026-11-10/immunotherapy-tumor-neighborhood/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-10/immunotherapy-tumor-neighborhood/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-10T00/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/disease-maps-get-granular/",
      "headline": "Dengue, malaria and heat deaths are being mapped at a finer grain",
      "slug": "disease-maps-get-granular"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/blood-tests-close-in-on-brain-disease/",
      "headline": "A blood test that tells brain from spine injury joins a week of brain biomarkers",
      "slug": "blood-tests-close-in-on-brain-disease"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-10/heart-risk-missed-in-younger-adults/",
      "headline": "Heart risk is visible earlier than the system acts on it",
      "slug": "heart-risk-missed-in-younger-adults"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-10/resistance-leaves-a-pattern/",
      "headline": "Resistance is not random: four preprints map where it hides",
      "slug": "resistance-leaves-a-pattern"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Run the cited Manifests yourself",
    "text": "Every claim in this paper points to a Manifest id. Get a Synorb Key and read the Manifests behind it. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons.",
    "cta": {
      "label": "Get a key",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-10/immunotherapy-tumor-neighborhood/"
  }
}